Camrelizumab-induced immune thyroid dysfunction
10.3760/cma.j.cn114015-20210913-00988
- VernacularTitle:卡瑞利珠单抗致免疫性甲状腺功能异常
- Author:
Chunyan YANG
1
;
Jing SONG
1
;
Jun LIU
1
;
Jiajie LUAN
1
Author Information
1. 皖南医学院弋矶山医院药学部，芜湖 241001
- Publication Type:Journal Article
- Keywords:
Immune checkpoint inhibitors;
Hyperthyroidism;
Hypothyroidism;
Camrelizumab
- From:
Adverse Drug Reactions Journal
2022;24(5):268-270
- CountryChina
- Language:Chinese
-
Abstract:
An 87-year-old female patient with advanced lung adenocarcinoma received an IV infusion of camrelizumab 200 mg once every three weeks. The patient developed hyperthyroidism before the 5th treatment, subclinical hypothyroidism before the 6th treatment, and clinical hypothyroidism before the 7th treatment. No other drugs were used during the treatment of camrelizumab, which was considered to be immune thyroid disfunction caused by camrelizumab. Levothyroxine sodium replacement therapy was given. The patients were followed up until the 13th treatment was finished. Except for the occasional high thyroid stimulating hormone, the other indexes were within the reference value range, and the symptoms of abdominal distension, anorexia, chills, and fatigue were basically relieved.
